CA1262682C - Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents - Google Patents

Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents

Info

Publication number
CA1262682C
CA1262682C CA506180A CA506180A CA1262682C CA 1262682 C CA1262682 C CA 1262682C CA 506180 A CA506180 A CA 506180A CA 506180 A CA506180 A CA 506180A CA 1262682 C CA1262682 C CA 1262682C
Authority
CA
Canada
Prior art keywords
solid phase
pyrogen
virus
treatment
pharmacological products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA506180A
Other languages
English (en)
French (fr)
Other versions
CA1262682A (en
Inventor
Sudhish Chandra
Fred Feldman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to CA506180A priority Critical patent/CA1262682C/en
Application granted granted Critical
Publication of CA1262682A publication Critical patent/CA1262682A/en
Publication of CA1262682C publication Critical patent/CA1262682C/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/20—Gaseous substances, e.g. vapours
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA506180A 1985-04-11 1986-04-09 Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents Expired CA1262682C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA506180A CA1262682C (en) 1985-04-11 1986-04-09 Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US722,561 1985-04-11
US06/722,561 US4673733A (en) 1985-04-11 1985-04-11 Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
CA506180A CA1262682C (en) 1985-04-11 1986-04-09 Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents

Publications (2)

Publication Number Publication Date
CA1262682A CA1262682A (en) 1989-11-07
CA1262682C true CA1262682C (en) 1989-11-07

Family

ID=24902372

Family Applications (1)

Application Number Title Priority Date Filing Date
CA506180A Expired CA1262682C (en) 1985-04-11 1986-04-09 Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents

Country Status (8)

Country Link
US (1) US4673733A (2)
EP (1) EP0197554B1 (2)
JP (1) JPS61275210A (2)
AT (1) ATE54828T1 (2)
AU (1) AU580402B2 (2)
CA (1) CA1262682C (2)
DE (1) DE3672868D1 (2)
DK (1) DK161786A (2)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212523A (en) * 1985-06-24 1989-01-06 Univ Massey Mobile phase for purification of proteins by high performance liquid chromatography
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
DE3707987A1 (de) * 1987-03-12 1988-09-22 Behringwerke Ag Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
DE69027187T2 (de) * 1989-06-15 1996-10-31 Rorer Int Overseas Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen
US5202246A (en) * 1989-08-16 1993-04-13 Armour Pharmaceutical Company Treatment of immobilized matrices for preparation of pharmaceutical and biological products with anti-microbial agents to remove pyrogen-producing organisms and pyrogens
AU6428390A (en) * 1989-08-16 1991-04-03 Rorer International (Overseas) Inc. Treatment of immobilized matrices with antimicrobial agents to remove pyrogen-producing organisms and pyrogens
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
JP3431142B2 (ja) * 1991-06-26 2003-07-28 パーセプティブ・バイオシステムズ・インコーポレイテッド 痕跡量混入物の検出方法及び装置
AT398079B (de) * 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
DE4142908C2 (de) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
WO1994013329A1 (de) * 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
DE4302163A1 (de) * 1993-01-27 1994-07-28 Thomae Gmbh Dr K Verfahren zur Reinigung von Proteinen und Peptiden
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
GB9407886D0 (en) * 1994-04-21 1994-06-15 Ici Plc Purification process
DE19544297A1 (de) * 1995-11-28 1997-06-05 Behringwerke Ag Verfahren zur Entfernung von aromatischen Verbindungen aus produkthaltigen Lösungen
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
IT1285551B1 (it) * 1996-01-30 1998-06-18 Paolo Giovannetti Composizione e procedimento per la sterilizzazione di substrati di coltura
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
BR9807936A (pt) 1997-04-08 2000-02-22 Baxter Ag Preparação farmacêutica imuno-tolerante de complexo de pró-trombina, processo para a produção de uma preparação, e, utilização de uma preparação
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
FR2772381B1 (fr) * 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
US6585890B2 (en) 2000-02-04 2003-07-01 Applied Research Associates, Inc. Process for producing sterile water for injection from potable water
GB0027047D0 (en) * 2000-11-06 2000-12-20 Ici Plc Process for reducing the concentration of undesired compounds in a composition
JP2002267642A (ja) * 2001-03-13 2002-09-18 Tosoh Corp アルカリ土類金属イオン測定用イオンクロマトグラフィー溶離液およびそれを用いたアルカリ土類金属イオン分析方法
AU2003246829A1 (en) 2002-02-19 2003-09-09 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
US7122149B2 (en) * 2002-07-12 2006-10-17 Applied Research Associates, Inc. Apparatus and method for continuous depyrogenation and production of sterile water for injection
WO2007085626A1 (en) * 2006-01-25 2007-08-02 Octapharma Ag Purification and use of a factor for supporting wound healing
ATE517192T1 (de) * 2006-08-10 2011-08-15 Merck Patent Gmbh Verfahren zur isolierung von zellen
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
DE202015100806U1 (de) 2015-02-19 2015-04-15 Paul Schaffrath Vorrichtung zur Inaktivierung von Krankheitserregern in Flüssigkeiten
JP6584803B2 (ja) * 2015-03-19 2019-10-02 国立大学法人滋賀医科大学 汎用性エンドトキシンフリー化処理方法
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
WO2025188996A1 (en) * 2024-03-06 2025-09-12 Bristol-Myers Squibb Company Antifoam compositions and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1767389A1 (de) * 1968-05-06 1971-09-02 Bayer Ag Verfahren zur Abtrennung von Pyrogenen aus Rohpraeparaten von L-Asparaginase
US4035316A (en) * 1975-11-24 1977-07-12 California Institute Of Technology Cell specific, variable density, polymer microspheres
JPS53113080A (en) * 1977-03-10 1978-10-03 Sumitomo Chem Co Ltd Purification of urokinase
US4305870A (en) * 1979-01-31 1981-12-15 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Intravenous plasma derivatives and their production
US4321363A (en) * 1980-02-21 1982-03-23 Nippon Soda Company Limited Adsorbent for urokinase containing agarose
US4411795A (en) * 1980-03-10 1983-10-25 Baxter Travenol Laboratories, Inc. Particle adsorption
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4412985A (en) * 1980-10-06 1983-11-01 Edward Shanbrom Depyrogenation process
US4380511A (en) * 1981-08-12 1983-04-19 Miles Laboratories, Inc. Purification of bovine thrombin
US4511556A (en) * 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
CA1208551A (en) * 1982-12-27 1986-07-29 Ricardo H. Landaburu Solvent treatment of plasma protein products
JPS6156133A (ja) * 1984-08-24 1986-03-20 Chemo Sero Therapeut Res Inst 発熱物質の除去方法

Also Published As

Publication number Publication date
AU5596086A (en) 1986-11-06
DK161786D0 (da) 1986-04-10
DE3672868D1 (de) 1990-08-30
US4673733A (en) 1987-06-16
CA1262682A (en) 1989-11-07
EP0197554A2 (en) 1986-10-15
JPS61275210A (ja) 1986-12-05
EP0197554A3 (en) 1987-03-25
DK161786A (da) 1986-10-12
AU580402B2 (en) 1989-01-12
JPH0578532B2 (2) 1993-10-29
ATE54828T1 (de) 1990-08-15
EP0197554B1 (en) 1990-07-25

Similar Documents

Publication Publication Date Title
CA1262682C (en) Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
FI99192B (fi) Menetelmä virusten inaktivoimiseksi veressä ja verituotteissa
DE69033509D1 (de) Laserverfahren zur Behandlung von Mikrokapseln oder Teilchen
DE69428130D1 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69829112D1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
DE69424917D1 (de) Verfahren und Vorrichtung zur ablativen Behandlung von elastomerischen Produkten
DE3683586D1 (de) Behandlung des atemunwohlseinsyndroms bei erwachsenen.
BE873695A (fr) Procede et preparation pour l'inactivation de virus et applications de ceux-ci pour des compositions pharmaceutiques et le traitement de matieres alimentaires
RU94045825A (ru) Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство
DK0722344T3 (da) Fremgangsmåde til virusinaktivering i nærvær af en polyether og et middel
DE69217239D1 (de) Verfahren zur behandlung von infiziertem abfall
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
FR2585572B3 (fr) Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
CA2191406A1 (en) Process for removing aromatic compounds from product-containing solutions
HU891056D0 (en) Process for treating the diseases of the gullet and the stomach-intestine system
DE69004451D1 (de) Prophylaxe und Behandlung von Herpesvirus-Infektionen.
FR2690152B1 (fr) Procede de preparation et de traitement de propulseurs.
ES2147200T3 (es) Uso de un veneno de himenopteros para la fabricacion de un medicamento para tratar infecciones por virus de adn.
FR2614203B1 (fr) Composition pharmaceutique pour le traitement des maladies de la peau et son procede de preparation.
PT77767B (fr) Procede de preparation de 3',5'-diarabinosides et de compositi-ons pharmaceutiques les contenant
DE59104484D1 (de) Verfahren und Vorrichtung zur Behandlung von feuchten Gas-Staub-Gemischen.
AU678404B2 (en) Process for the purification and concentration of rubella virus
FR2674536B1 (fr) Procede d'inactivation de virus et composition pharmaceutique pour l'inactivation de virus.
DE3883754D1 (de) Mittel zur prophylaxe und behandlung von viralen infektionskrankheiten.

Legal Events

Date Code Title Description
MKLA Lapsed
MKLA Lapsed

Effective date: 20051107